In general, systemic drugs do not help with dry eye and dry mouth, and thus, clinicians need to rely on local treatment options. Systemic drugs, such as rituximab, may, however, be effective for extra-glandular disease and other symptoms of Sjögren’s. Criteria have been developed for better patient selection and more appropriate outcome measures for the many clinical trials currently underway. In this way we can position patients to benefit as new drugs become available.
Coordination of Care
The speakers agreed that, not only is the diagnosis of Sjögren’s syndrome difficult, but the treatment of patients with Sjögren’s syndrome can be complex. “Many specialists are required, and someone needs to coordinate them. That’s your job,” emphasized Dr. Bookman.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
